

FULCRUM PHARMA PLC
("the Group" or "the Company")

Official Opening of Edinburgh Office to Serve Growing European Customer Base

Fulcrum Pharma plc (AIM: FUL), the drug development and strategic outsourcing services company, is pleased to announce that it has opened an office in Edinburgh with the assistance of a grant of up to £150,000 from the Scottish Executive as part of the Group's planned expansion.

The Edinburgh office, which is located at the Heriot-Watt University Research Park, will complement Fulcrum's other UK offices in Hemel Hempstead, Hertfordshire, and Midhurst, Kent, and its office in Strasbourg, France, and will allow the Group to further develop the depth of the Group's resources in drug development, project management and regulatory affairs.

Staff recruitment has already begun at the Edinburgh office and Fulcrum is benefiting from both the pool of experienced talent in the region and from people who are relocating to the Edinburgh area.

The opening of the Edinburgh office is part of the Group's planned expansion, which is seeing Fulcrum increase both the range of its services and the volume of work it is able to carry out for its international client base.

Jon Court, Chief Executive of Fulcrum Pharma, said: "I am very pleased with the opening of the Edinburgh office, which fulfils a strategic objective in that it allows scale-up of our business at a time when the outsourcing of drug development is enjoying increasing prominence in the biotechnology and pharmaceutical industries."

FOR FURTHER INFORMATION, PLEASE CONTACT:

Fulcrum Pharma PLC
Ashley Nagle, Business Development
Edinburgh Office

Tel:+44 1442 283 600
Tel: +44 131 449 8888

Notes for editors

About Fulcrum Pharma plc

Fulcrum Pharma plc is an independent, drug development company that offering global virtual drug development and strategic outsourcing services to the pharmaceutical industry. The Group is expert in the design, execution and delivery of drug development programmes and works with emerging biotech / pharma companies as well larger Pharma companies.

Through Fulcrum Pharma's services to its clients, the Directors believe that there is the capacity to deliver products faster and more efficiently to the global pharmaceutical market. Fulcrum Pharma does this by using its skills in the design of drug programmes that deliver the necessary information for decision-making and product development. In so doing, Fulcrum Pharma works closely with its clients to meet their strategic R&D goals.

Fulcrum Pharma is listed on the Alternative Investment Market of the London Stock Exchange having successfully floated in March 2000.